Clinical Trial Update: Pembrolizumab in Neoplasms or Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 trial of pembrolizumab for lymphomas and dendritic cell sarcomas is suspended, with results posted in November 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Dendritic Cell Sarcoma
• Histiocytic Sarcoma
• Interdigitating Dendritic Cell Sarcoma
• Lymphoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Lymphoma, Histiocytic Sarcoma | Phase 2 | Status: SUSPENDED | Results posted: 2023-11-22